Trigeminal Neuralgia

• Vascular Compression and Microvascular Decompression Hypothesis: The most widely accepted mechanism involves compression of the trigeminal nerve root (most commonly by the superior cerebellar artery or vertebral artery) at the entry zone into the brainstem. This chronic mechanical compression causes demyelination of myelinated Aα and Aβ fibers, which normally transmit innocuous touch and proprioception. The demyelination creates "naked" axonal segments that generate ectopic action potentials and exhibit cross-talk (ephaptic transmission) between adjacent axons. This pathophysiology explains why trivial stimuli (touching the face, brushing teeth, chewing) trigger severe pain: low-threshold sensory inputs intended to activate touch receptors instead activate pain-transmission systems due to abnormal coupling. Electrophysiological studies show shortened refractory periods and increased spontaneous activity in demyelinated segments, establishing the cellular basis for paroxysmal attacks.

• Central Sensitization and Trigeminal Nucleus Dysfunction: Beyond peripheral pathology, central sensitization within the medullary dorsal horn and trigeminal nucleus caudalis perpetuates pain signaling. Chronic peripheral nociceptive input leads to reduced threshold for activation of wide-dynamic-range (WDR) neurons in the trigeminal nucleus, increased receptive field sizes, and prolonged afterdischarges. Wind-up phenomena—the temporal summation of C-fiber input leading to progressively increased neuronal response—occurs more readily in sensitized neurons. Additionally, loss of descending inhibition from brainstem pain-modulatory systems (including serotonergic and noradrenergic pathways from the rostral ventromedial medulla) contributes to disinhibition of trigeminal pain processing. Functional imaging studies demonstrate abnormal brain connectivity in TN patients, consistent with this central component.

• Ion Channel Dysfunction and Membrane Excitability: Sodium channel abnormalities have been demonstrated in trigeminal neurons in both primary and secondary TN. Altered expression and function of voltage-gated sodium channels (particularly Nav1.7 and Nav1.8) increase neuronal hyperexcitability and spontaneous firing. Furthermore, dysfunction in potassium channels (K+ channels regulate membrane repolarization) reduces hyperpolarizing capacity, maintaining neurons in a hyperexcitable state. These channelopathies explain the dramatic response to sodium channel-blocking medications (carbamazepine) and provide a rationale for emerging genetic studies in familial cases.

• Inflammatory and Neuroplastic Changes: Emerging evidence implicates neuroinflammation at the site of vascular compression, with activation of microglia and release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) contributing to hyperexcitability. Additionally, synaptic plasticity changes and altered expression of pain-related neurotransmitter receptors (NMDA, AMPA, kainate receptors) further sensitize trigeminal pain circuits. These mechanisms explain why some patients develop progressive, more frequent attacks over time and why early intervention may prevent progression.

• Primary (Idiopathic) Trigeminal Neuralgia (~90% of cases): No identifiable structural lesion on imaging; most have evidence of vascular compression of the trigeminal root entry zone at the brainstem. Risk increases with age (peak 50-70 years) and female predominance (female-to-male ratio ~1.5:1). Hypertension and atherosclerosis may increase likelihood of vascular compression by affecting vessel compliance and positioning. A small percentage of primary TN cases show familial clustering, suggesting potential genetic predisposition to pain sensitization or vascular abnormalities.

• Secondary Trigeminal Neuralgia (10-15% of cases): Multiple sclerosis (MS) is the most common identifiable cause in younger patients (<40 years), present in 2-5% of TN patients and in 1-5% of MS patients; plaque-induced demyelination of the trigeminal nerve mimics idiopathic disease pathophysiology. Cerebellopontine angle lesions (acoustic neuromas, meningiomas) compress the nerve distally. Brainstem tumors, cavernous sinus pathology, and skull base lesions mechanically impinge the trigeminal nerve. Post-herpetic trigeminal nerve injury from herpes zoster can produce a delayed neuropathic pain syndrome resembling TN. Arteriovenous malformations, aneurysms, and other vascular lesions can cause compression similar to benign vascular overlap.

• Additional Risk Factors: Advanced age, female sex, and presence of systemic hypertension increase susceptibility. Connective tissue disorders (scleroderma, Sjögren's syndrome) and autoimmune conditions may predispose through vascular and inflammatory mechanisms. Antecedent facial trauma, dental procedures, or herpes zoster infection along the trigeminal distribution may precipitate onset in susceptible individuals.

• Cardinal Symptom: Unilateral Lancinating Pain: The hallmark is sudden-onset, severe, electric shock-like or stabbing pain confined to the distribution of the trigeminal nerve (V1 ophthalmic, V2 maxillary, or V3 mandibular division); bilateral presentation occurs in <5% and suggests secondary pathology. Pain episodes typically last seconds to 2 minutes (most commonly 10-120 seconds), though in severe cases patients may report multiple attacks clustering over hours. Pain intensity is often described as "worst pain imaginable" on a pain scale, driving patients to seek urgent evaluation and driving the high morbidity. The sudden, paroxysmal nature—pain-free intervals between attacks—is pathognomonic and distinguishes TN from other facial pain disorders.

• Trigger Factors and Provocation: Most patients identify specific triggers (trigger zones) that precipitate attacks—light touch to the face, chewing, speaking, tooth-brushing, wind exposure, or even spontaneous. Triggers are typically ipsilateral to the pain and often clustered in perioral/perinasal regions. This trigger-evoked pattern reflects the demyelination-induced ephaptic transmission mechanism: light touch activates normally low-threshold mechanoreceptors that have become coupled with pain-signaling fibers. Some patients develop "refractory periods" after attacks during which triggers are ineffective, suggestive of sodium channel inactivation.

• Pain Characteristics and Distribution: Pain is strictly unilateral (always a red flag if bilateral); most commonly affects V3 (mandibular, 40-50%) > V2 (maxillary, 30-35%) > V1 (ophthalmic, 15-20%), with V2-V3 overlap common. Pain distribution respects strict trigeminal dermatomes without crossing midline. Attacks may be seasonal or follow circadian patterns. Some patients report pain radiating from the trigger zone inward toward the brainstem, suggesting centripetal propagation along the trigeminal pathway.

• Physical Examination Findings: Neurologic examination is typically completely normal between attacks in primary TN—this normal exam is expected and reassuring. Notably, while some patients may exhibit light touch hypoalgesia in the affected division (consistent with demyelination-induced sensory loss), motor division testing (masseter strength, jaw deviation) and corneal reflex testing should be intact. The absence of objective sensory loss can paradoxically reassure about primary (benign) disease; significant sensory loss suggests structural pathology compressing the nerve.

• Important Clinical Variants: Atypical Trigeminal Neuralgia presents with constant, burning, or dull pain superimposed on typical lancinating episodes; this variant may be more refractory to treatment. Trigeminal Neuralgia 2 (TN2) involves paroxysmal stabbing pain with concomitant constant background burning/aching, representing a mixed phenotype with worse prognosis. Secondary TN associated with MS may present earlier in life (30s-40s), be bilateral in ~10% of MS patients, and may precede other MS manifestations.

• Clinical Diagnostic Criteria (International Headache Society/IHS): TN is diagnosed when recurrent episodes of unilateral facial pain meet the following: (1) pain in distribution of one or more divisions of CN V; (2) pain has at least three of these features: sudden onset, severe intensity, lancinating/electric shock quality, triggered by innocuous stimuli; (3) attacks are stereotyped in individual; (4) no ipsilateral neurologic deficit; (5) attacks occur at least 4 times per day over several days, or shorter duration with 8+ per day; (6) not better explained by another diagnosis. These criteria distinguish TN from atypical facial pain (burning quality, no triggers), postherpetic neuralgia (dermatomal distribution, history of zoster), and neuropathic pain syndromes (continuous rather than paroxysmal).

• Imaging and Differential Diagnosis Role: Magnetic Resonance Imaging (MRI) of the brain is essential for first presentation to exclude secondary causes, particularly in patients <40 years, with bilateral pain, progressive neurologic deficit, or atypical features. T2-weighted and FLAIR sequences best visualize trigeminal nerve compression by vessels; CISS (Constructive Interference in Steady State) sequences provide high anatomic detail of the nerve root entry zone. MRI identifies demyelinating lesions of MS (in 20-30% of TN patients; presence of MS lesions predicts poorer medical treatment response). CT imaging is less sensitive for subtle pathology but may identify osseous abnormalities or skull base lesions. Sensory testing (quantitative sensory testing, QST) is not routinely performed but when abnormal suggests secondary etiology. Trigeminal Reflex Testing: Corneal reflex (V1-trigeminal sensory, CN VII motor) and masseter reflex (V3-afferent) should be normal in primary TN; abnormalities suggest demyelinating disease or compressive lesion.

• Neurophysiologic Testing: Electromyography/Nerve Conduction Studies (EMG/NCS) are not routinely diagnostic but trigeminal reflex blink reflex testing may show prolonged latencies or abnormal responses in demyelinating conditions. Trigeminal Somatosensory Evoked Potentials (tSSEP) are research tools but not clinically standardized.

• Differential Diagnostic Considerations: Postherpetic neuralgia presents with constant burning pain in dermatomal distribution with prior history of zoster; typically responds poorly to anticonvulsants. Atypical odontalgia involves dental pain without dental pathology; teeth testing and dental imaging are negative. Migraine with facial pain is typically longer-duration attacks with migrainous features (photophobia, nausea). Glossopharyngeal neuralgia involves CN IX distribution (throat, ear, tongue base) triggered similarly; much rarer. Occipital neuralgia involves C2 distribution (posterior scalp). SUNCT syndrome (Short-lasting Unilateral Neuralgiform pain with Conjunctival injection and Tearing) presents with orbital pain, lacrimation, and conjunctival injection—a primary headache disorder.

• First-Line Pharmacotherapy: Carbamazepine: Mechanism: Sodium channel blocker that inhibits repetitive firing along demyelinated trigeminal nerve fibers; also enhances GABA-mediated inhibition. Dosing: Initial dose 100-200 mg twice daily, titrated by 100-200 mg/day every 2-4 days up to therapeutic range of 400-1200 mg/day in divided doses (or up to 1600 mg/day in refractory cases); extended-release formulations improve tolerability. Efficacy: 60-80% of patients achieve pain relief; onset of action typically 24-72 hours, allowing rapid assessment of response. Monitoring: Baseline CBC, CMP, and LFTs mandatory; repeat at 2-4 weeks, then periodically (3-6 months). Monitor for hyponatremia (occurs in 10-30%, more common in elderly; SIADH mechanism); if sodium <130 mEq/L, consider dose reduction or fluid restriction. Adverse Effects: Dizziness, diplopia, ataxia (dose-dependent, often improve with titration), sedation, nausea. Rare but serious: aplastic anemia (incidence 1-2 per 100,000; monitor for fever, sore throat, easy bruising), Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (TEN, especially in patients of Asian descent; screen for HLA-B*1502 allele if ancestry suggests risk), and hepatotoxicity. Drug Interactions: Induces CYP3A4 and CYP2C9; reduces efficacy of oral contraceptives, warfarin, corticosteroids, and other medications.

• Second-Line/Alternative Anticonvulsants: Oxcarbazepine (300-2400 mg/day divided doses) is structurally similar to carbamazepine with sodium channel blockade; fewer drug interactions and better tolerability but slightly lower efficacy (~60%). Hyponatremia still occurs (though ~25% as frequent as carbamazepine). Phenytoin (300-400 mg/day divided doses) is older sodium channel blocker with more toxicity and more frequent monitoring needed; reserved for patients intolerant to carbamazepine/oxcarbazepine. Levetiracetam and topiramate have emerging evidence from small series but less robust data than first/second-line agents.

• Adjunctive Pharmacotherapy for Inadequate Response: Baclofen (10-80 mg/day in divided doses; GABA-B agonist) can be added to anticonvulsants; works synergistically and may allow dose reduction of primary agent. Gabapentin (900-3600 mg/day in 3 divided doses; calcium channel blocker) is less effective as monotherapy but useful adjunct. Tricyclic Antidepressants: Amitriptyline (25-100 mg nightly) provides adjunctive benefit, particularly if concurrent depression/anxiety. Lamotrigine (50-400 mg/day) has mixed evidence; may be beneficial in MS-related TN. Botulinum Toxin A (intramuscular injection into trigger zones; 25-50 units per site) blocks acetylcholine release and inhibits nociceptive neurotransmitter release; anecdotal reports support use in refractory cases, though evidence is limited.

• Management of Refractory Cases (Surgical/Interventional Options): For patients with inadequate response to or intolerance of medical therapy (~25-30% of patients), interventional procedures become necessary. Microvascular Decompression (MVD): Neurosurgical gold standard; via retrosigmoid approach, identifies vascular compression and interposes Teflon or other material between vessel and nerve. Success rate 70-90% for pain relief; recurrence rate 10-30% over 10-15 years; mortality ~0.5% in experienced centers. Reserved for medically refractory patients with radiographic evidence of vascular compression. Percutaneous Balloon Microcompression: Catheter placed through foramen ovale, inflated balloon compresses trigeminal ganglion; success rate 60-90%, recurrence rate 40% at 3 years. Procedure causes temporary or permanent facial hypoesthesia in 50% of patients—acceptable trade-off for pain relief in severe cases. Percutaneous Radiofrequency Ablation (RFA): Radiofrequency lesioning of trigeminal nerve/ganglion; success rate 60-90%, recurrence rate similar to balloon compression. Stereotactic Gamma Knife Radiosurgery: Focused radiation to trigeminal

Disease-related

• Nutritional and hydration compromise: chewing, drinking, and even oral hygiene are trigger stimuli, so patients avoid eating and dental care; the signal is unintentional weight loss, dehydration, or advanced dental caries on the affected side.
• Psychiatric morbidity: relentless paroxysmal pain plus anticipatory fear of triggers produces depression, anxiety, and social isolation. TN has historically and colloquially been called the suicide disease; this is a lay designation, and elevated suicide risk is described in case series and clinical reports rather than established incidence data. Active suicidal ideation is an emergency requiring same-visit risk assessment (APA practice guidance).
• Missed secondary cause: progressive sensory loss, corneal reflex depression, masseter weakness, bilateral pain, or onset at a young age signals multiple sclerosis, a cerebellopontine angle tumor, or other structural lesion — urgent MRI, not dose escalation.

Treatment-related

• Carbamazepine hypersensitivity (SJS/TEN, DRESS): mucosal erosions, target lesions, or a rash with fever and eosinophilia are dermatologic emergencies — stop the drug immediately. FDA labeling advises HLA-B*15:02 testing before starting carbamazepine in patients of Asian ancestry.
• Aplastic anemia/agranulocytosis: bone marrow suppression presenting as fever, sore throat, or easy bruising; obtain an urgent CBC and discontinue. Benign leukopenia is far more common and does not always require stopping.
• Hyponatremia (SIADH-like potentiation of ADH effect): occurs with both agents and is generally more frequent with oxcarbazepine than carbamazepine; risk rises with advancing age, thiazide co-therapy, and higher doses. Confusion, gait instability, or new seizures signal it, and severe symptomatic hyponatremia is an emergency.
• Enzyme induction: carbamazepine induces CYP3A4/2C9 and also P-glycoprotein, lowering levels of combined oral contraceptives, warfarin, and — via combined CYP3A4 plus P-gp induction, per product labeling and pharmacologic data — direct oral anticoagulants. Contraceptive failure and unplanned pregnancy on a teratogenic antiepileptic (neural tube defects) is a classic tested consequence.
• Baclofen withdrawal: abrupt cessation can precipitate seizures, hallucinations, and rebound hypertonia — an emergency; taper instead.
• Ablative procedure sequelae: radiofrequency, balloon compression, and radiosurgery all injure the ganglion or root. Anesthesia dolorosa — severe pain in a numb territory — is largely irreversible and treatment-resistant. Corneal anesthesia after V1 lesioning risks neurotrophic keratitis and ulceration; a red or hazy eye warrants urgent ophthalmology referral.
• Microvascular decompression risks: CSF leak and bacterial meningitis (emergency), ipsilateral hearing loss from CN VIII traction, cerebellar hematoma or infarct with acute headache and ataxia (emergency), and aseptic meningitis.

• The stem's buzzwords: unilateral, electric shock-like or lancinating facial pain lasting seconds, triggered by shaving, chewing, cold wind, or tooth-brushing, with complete pain-free intervals and a normal neurologic exam. That combination is trigeminal neuralgia until proven otherwise.
• Single best next step at first presentation: MRI of the brain (thin-section sequences through the posterior fossa) to exclude secondary causes, then start carbamazepine, the sodium channel blocker with the strongest evidence and the AAN/EFNS first-line recommendation. Oxcarbazepine is the alternative when interactions or monitoring burden matter.
• The association examiners love: TN before roughly age 40–50, or bilateral TN, should raise strong suspicion for a secondary cause — multiple sclerosis is the classic one on exams (a demyelinating plaque at the root entry zone reproduces the same ephaptic mechanism as vascular compression), but a cerebellopontine angle tumor or other structural lesion must be excluded by MRI. Look for internuclear ophthalmoplegia or prior optic neuritis in the stem.
• The vessel to name: the superior cerebellar artery compressing the root entry zone is the classic culprit in idiopathic disease and the target of microvascular decompression.
• Before you prescribe carbamazepine: baseline CBC, sodium, and LFTs, plus **HLA-B*15:02 screening in patients of Asian ancestry** per FDA labeling because of SJS/TEN risk. Recheck sodium — hyponatremia is a common and easily missed cause of dose limitation in older adults, along with dizziness, ataxia, and sedation, which are the usual reasons therapy is stopped.
• Common distractor — the dentist: V2/V3 pain is repeatedly misattributed to dental disease, and unnecessary extractions or root canals are the classic wrong answer. Normal dental exam and imaging with paroxysmal triggered pain point away from odontogenic causes.
• Distinguish the mimics: cluster headache is longer (15–180 minutes), orbital, with ipsilateral autonomic features; postherpetic neuralgia is constant and burning with prior zoster; SUNCT has conjunctival injection and tearing; giant cell arteritis causes jaw claudication with chewing, not shock-like paroxysms.
• Red flags that overturn the diagnosis: objective sensory loss, depressed corneal reflex, masseter weakness, or progressive rather than paroxysmal pain — image for a cerebellopontine angle mass.